Private company developing AMD tri-specific that_hits VEGF-A/VEGF-C/Ang-2: https://www.prnewswire.com/news-releases/revopsis-secures-16-5-million-seed-funding-to-advance-first-in-class-tri-specific-therapy-for-neovascular-amd-treatment-302127081.html